Cargando…
Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK–Rearranged NSCLC
Autores principales: | Daniel, Catherine, Callens, Celine, Melaabi, Samia, Bieche, Ivan, Girard, Nicolas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474206/ https://www.ncbi.nlm.nih.gov/pubmed/34589961 http://dx.doi.org/10.1016/j.jtocrr.2020.100082 |
Ejemplares similares
-
A Naive Lung Adenocarcinoma Harboring G1269A ALK Resistance Mutation
por: Trabelsi-Grati, Olfa, et al.
Publicado: (2020) -
Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
por: Tran, Phu N., et al.
Publicado: (2016) -
Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
por: Takeyasu, Yuki, et al.
Publicado: (2022) -
Two Uncomplicated Pregnancies on Alectinib in a Woman With Metastatic ALK-Rearranged NSCLC: A Case Report
por: Weidenbaum, Chloe, et al.
Publicado: (2022) -
The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC
por: Huang, Xing
Publicado: (2018)